MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Christine E. Ryan(Dana-Farber Cancer Institute), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Sarang Abhyankar(Acentech (United States)), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Hasan Alhasani(AbbVie (United States)), Richard Hermann(AstraZeneca (Netherlands)), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Juliana M.L. Biondo, Mina Shahkarami(AstraZeneca (Netherlands))
Cited by 35
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k